EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS-Reference-Cited by-同舟云学术

EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS

Published:2022-12 Issue: Volume: Page:
ISSN:1569-1993
Container-title:Journal of Cystic Fibrosis
language:en
Short-container-title:Journal of Cystic Fibrosis

Author:

Lee Tim,Sawicki Gregory S.,Altenburg Josje,Millar Stefanie J.^ORCID,Geiger Jessica Morlando,Jennings Mark T.,Lou Yiyue^ORCID,McGarry Lisa J.,Van Brunt Kate,Linnemann Rachel W.

Funder

Vertex Pharmaceuticals Incorporated

Cystic Fibrosis Foundation

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Reference10 articles.

1. Year-to-year changes in lung function in individuals with cystic fibrosis;Liou;J Cyst Fibros,2010

2. VanDevanter DR. Characterizing aggressiveness and predicting future progression of CF lung disease;Konstan;J Cyst Fibros,2009

3. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis;Corey;J Pediatr,1997

4. Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data;Sawicki;Am J Respir Crit Care Med,2015

5. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study;Konstan;Lancet Respir Med,2017

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Retrospective, Longitudinal Registry Study on the Long-Term Durability of Ivacaftor Treatment in People with Cystic Fibrosis;Pulmonary Therapy;2024-09-12

2. Cystic fibrosis;Nature Reviews Disease Primers;2024-08-08

3. CFTR Modulators Therapy Efficacy in Reducing Cystic Fibrosis (CF) Exacerbation and Improving Selected Spirometry Parameters: A Real-Life Study in a Single-Centre Polish Population;Journal of Clinical Medicine;2024-07-31

4. Cystic fibrosis year in review 2023;Pediatric Pulmonology;2024-07-26

5. Real-world impact of ivacaftor in people with cystic fibrosis and select ivacaftor-responsive mutations;BMJ Open Respiratory Research;2024-07